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Abstract
Mitochondrial dysfunction including that caused by oxidative stress has been implicated in the pathogenesis of
neurodegenerative diseases. Glutaredoxin 1 (Grx1), a cytosolic thiol disulfide oxido-reductase, reduces glutathionylated
proteins to protein thiols and helps maintain redox status of proteins during oxidative stress. Grx1 downregulation
aggravates mitochondrial dysfunction in animal models of neurodegenerative diseases, such as Parkinson’s and motor
neuron disease. We examined the mechanism underlying the regulation of mitochondrial function by Grx1. Downregulation
of Grx1 by shRNA results in loss of mitochondrial membrane potential (MMP), which is prevented by the thiol antioxidant, a-
lipoic acid, or by cyclosporine A, an inhibitor of mitochondrial permeability transition. The thiol groups of voltage
dependent anion channel (VDAC), an outer membrane protein in mitochondria but not adenosine nucleotide translocase
(ANT), an inner membrane protein, are oxidized when Grx1 is downregulated. We then examined the effect of b-N-oxalyl
amino-L-alanine (L-BOAA), an excitatory amino acid implicated in neurolathyrism (a type of motor neuron disease), that
causes mitochondrial dysfunction. Exposure of cells to L-BOAA resulted in loss of MMP, which was prevented by
overexpression of Grx1. Grx1 expression is regulated by estrogen in the CNS and treatment of SH-SY5Y cells with estrogen
upregulated Grx1 and protected from L-BOAA mediated MMP loss. Our studies demonstrate that Grx1, a cytosolic oxido-
reductase, helps maintain mitochondrial integrity and prevents MMP loss caused by oxidative insult. Further,
downregulation of Grx1 leads to mitochondrial dysfunction through oxidative modification of the outer membrane
protein, VDAC, providing support for the critical role of Grx1 in maintenance of MMP.
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Introduction
Mitochondria play a pivotal role in cell function both in terms of
being the power centers of the cell as well as mediators of cell
death through apoptosis. Mitochondrial dysfunction has been
implicated in a variety of neurodegenerative disorders. For
example, abnormalities in mitochondrial complex I have been
observed in several infantile and childhood neurological disorders
and in neurodegenerative diseases such as Parkinson’s disease [1,2]
and motor neuron disease [3] while complex II dysfunction is seen
in Huntington’s disease [4,5]. The mechanisms underlying the
dysfunction and their role in neurodegeneration are not entirely
clear although it is generally believed that oxidative stress is a key
player in some of these events [6]. While a close association and
synergistic interplay exists between oxidative stress, mitochondrial
dysfunction and neurodegeneration, clear identification of the
events being either causative or consequential is yet to emerge.
Earlier studies with animal models of Parkinson’s disease have
shown that glutathione (GSH) loss and oxidative stress may
precede complex I dysfunction [7] and further, the loss of complex
I activity can be restored by thiol antioxidants [8]. These
observations clearly point to the role of oxidative stress as a
causative factor in complex I dysfunction.
b-N-oxalyl amino-L-alanine (L-BOAA, also known as b-N-
oxalyl-a,b-diamino propionic acid, b-ODAP; [9]) is an excitatory
amino acid that acts as an agonist for the AMPA sub-class of
glutamate receptors [10,11]. Ingestion of the chickling pea that
contains L-BOAA as the sole source of cereal leads to the
development of a type of motor neuron disease known as
neurolathyrism. The pathological hallmark of this disease includes
degeneration of anterior horn cells and loss of axons in the
pyramidal tracts in lumbar spinal cord in humans. Oxidative stress
and mitochondrial dysfunction are major contributors to L-BOAA
induced toxicity [12,13]. L-BOAA causes GSH loss and increase in
protein-glutathione mixed disulfides (PrSSG) in lumbosacral cord of
male mice [3] resulting in selective inhibition of mitochondrial
complex I, a major component of the mitochondrial electron
transport chain, due to oxidation of critical thiol groups [13].
Thiol disulfide oxido-reductases are a group of enzymes that
catalyze disulfide interchange reactions including conversion of
glutathionylated proteins (PrSSG) to protein thiols (PrSH). This
class of enzymes include glutaredoxin [14,15], thioredoxin and
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hydrogen donor systems, a thioredoxin system and a GSH
dependent glutaredoxin system [17]. Glutaredoxin 1 (also known
as thioltransferase; Grx1), a cytosolic thiol disulfide oxido-reductase
isolated from calf thymus [18] and human placenta [19] shows a
GSH-disulfide transhydrogenase activity [20] and specifically and
efficiently reduces glutathionylated proteins to protein thiols
[21,22], whereas thioredoxin and protein disulfide isomerase have
broad substrate specificities [23]. Glutaredoxin 1 senses cellular
redox potential and catalyzes glutathionylation, an important redox
regulatory mechanism in response to oxidative stress [24]. Grx1 is
essential for maintenance of complex I function in normal
conditions [25] and its upregulation is critical for recovery of
complex I function following L-BOAA administration [13].
Grx1 is a cytosolic protein and therefore its ability to influence
mitochondrial function in this manner is not anticipated. In the
present study we have examined the role of Grx1 in maintenance
of mitochondrial membrane potential by downregulating Grx1
expression using shRNA to Grx1 in cultured neuroblastoma cells.
Further, we have also exposed cells to the excitatory amino acid L-
BOAA and studied the interplay between Grx1 and mitochondrial
membrane potential. We have earlier observed that constitutive
expression of Grx1 is significantly higher in female brain regions as
compared to the male brain. Downregulation of Grx1 in female
mouse brain renders them vulnerable to L-BOAA mediated
mitochondrial dysfunction in a manner similar to that seen in male
mice [26]. We therefore studied the effect of estrogen on
expression of Grx1 and the ability of estrogen to protect against
mitochondrial dysfunction mediated by L-BOAA.
Results
Downregulation of Grx1 generates reactive oxygen
species
Grx1 is a cytosolic protein disulfide oxido-reductase, while
Grx2, another member of dithiol glutaredoxin enzyme family is
localized essentially in the mitochondria and the nucleus [27–30].
In order to confirm the localization of Grx1 in the cytoplasm,
Neuro-2a cells were loaded with MitoTracker (Deep Red 633) and
immunostained with antibody to Grx1 or Grx2. We observed that
Grx1 did not colocalize with MitoTracker confirming its
cytoplasmic localization, unlike Grx2, which completely coloca-
lized with MitoTracker (Fig. 1A). In order to generate cells in
which Grx1 was downregulated, we transiently transfected Neuro-
2a cells with shRNA to Grx1 and observed a consistent
knockdown of Grx1 after 72 hr. The immunoblot of Grx1 from
cells in which Grx1 was knocked down is shown (Fig. 1C). We used
qRT-PCR to quantify the altered expression of Grx1 and Grx2 in
these cells (Fig. 1B). While expression of Grx1 was significantly
reduced in cells transfected with shRNA, Grx2 levels were
unaffected indicating the specificity of the shRNA. The alteration
in the expression of Grx1 was also validated by immunohisto-
chemistry (Fig. 1D). Downregulation of Grx1 leads to generation
of reactive oxygen species as seen by H2DCFDA (29,79-
dichlorodihydrofluorescein diacetate) staining (Fig. 1E).
Optimum downregulation of Grx1 leads to alteration in
mitochondrial membrane potential
We qualitatively examined the mitochondrial membrane
potential (MMP) using JC-1 dye in Neuro-2a cells, wherein
Grx1 was silenced, after 72 hr after transfection of shRNA to
Grx1. JC-1 is a cationic dye which exhibits a potential dependent
accumulation in mitochondria which is indicated by a shift in the
fluorescence emission. In polarized mitochondria, it accumulates
in aggregated form and appears as red punctate staining whereas
in cells having depolarized mitochondria, it disseminates into the
cytoplasm and appears as green diffused monomeric staining. We
observed a time dependent loss of MMP which was maximum at
72 hour post-transfection in Neuro-2a cells (Fig. 2A, B).
Loss of MMP following Grx1 downregulation
MMP was quantified by real time imaging of live cells loaded
with mitochondrial potential sensitive dye TMRM in Neuro-2a
cells. Under normal conditions TMRM sequesters in the polarized
mitochondria and shows punctate staining. As the mitochondrial
membrane potential is lost, it diffuses out into the cytoplasm and
subsequently moves out of the plasma membrane. To quantify the
MMP, the fluorescence intensity was measured in several regions
of interest (ROI) representing TMRM stained mitochondria in live
cells. Under identical dye loading protocol the TMRM fluores-
cence in cells transfected with shRNA to Grx1 was significantly
lower as compared to those transfected with empty vector and did
not decrease further with time suggesting that the loss of MMP has
already occurred (Fig. 3B,E). To confirm that the decrease in
TMRM fluorescence is indeed due to loss of MMP, the
protonophore carbonyl cyanide m-chlorophenyl hydrazone
(CCCP) was added to depolarize the mitochondrial membrane.
CCCP induced an abrupt decrease in TMRM fluorescence
reflecting the loss of MMP. The decrease in relative change in
fluorescence intensity (DF/F) at 300 sec after CCCP addition was
considered as the relative measure of MMP. Downregulation of
Grx1 resulted in loss of MMP in Neuro-2a cells (Fig. 3B,E) as
compared to control cells transfected with empty vector (Fig. 3A,E)
and this loss of MMP was abolished by a-lipoic acid (Fig. 3C,E) or
cyclosporine A (Fig. 3D,E).
Perturbation of mitochondrial membrane potential in
response to Grx1 downregulation in SH-SY5Y, human
neuroblastoma cell line
We also examined the effects of downregulation of Grx1 in a
neuroblastoma cell line of human origin, namely the SH-SY5Y
cells, which express estrogen receptors and are sensitive to
excitotoxicty. The decrease in levels of Grx1 protein was examined
by immunocytochemistry (Fig. 4A), qRT-PCR (Fig. 4B) and
immunoblot analysis (Fig. 4C). Downregulation of Grx1 in SH-
SY5Y cells resulted in loss of MMP and prior exposure to a-lipoic
acid (100 mM), prevented the loss of MMP caused by Grx1
knockdown. Cyclosporine A (10 mM), an inhibitor of mitochon-
drial permeability transition pore (mPTP) also helped maintain
MMP (Fig. 4D) as examined using the JC-1 dye.
Loss of MMP caused by Grx1 knockdown is rescued by an
antioxidant or mPTP blocker
Loss of MMP was quantified using TMRM in SH-SY5Y cells.
Pseudocolor fluorescence images of TMRM loaded SH-SY5Y
cells captured before and after CCCP addition revealed the MMP
status in mitochondria of the cells transfected with empty vector or
shRNA to Grx1 (Fig. 5A). MMP loss was measured as decrease in
TMRM intensity. While there was a sharp drop in the
fluorescence in cells transfected with empty vector (Fig. 5B; a,e),
similar decrease was not observed in cells transfected with shRNA
to Grx1 (Fig. 5B; b,e), confirming that the MMP was already lost
in these cells. However, pretreatment of cells with a-lipoic acid
(Fig. 5B; c, e) or cyclosporine A (Fig. 5B; d,e) prevented the loss of
MMP.
Grx1-Mitochondrial Dysfunction
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loss and cell death
A stable cell line overexpressing Grx1 was generated by
electroporating SH-SY5Y with 20 mg of linearized construct
overexpressing Grx1, followed by clonal selection. Overexpression
of Grx1 was validated by immunocytochemistry (Fig. 6A), qRT-
PCR analysis (Fig. 6B) and immunoblot analysis (Fig. 6C).
Overexpression of Grx1 prevented the loss of cell viability seen
after L-BOAA (1 mM) treatment indicating that Grx1 offered
protection against L-BOAA mediated cell death (Fig. 6D).
Exposure of SH-SY5Y cells to L-BOAA (1 mM) resulted in loss
of MMP which was not seen in cells overexpressing Grx1 as
observed using JC1 dye (Fig. 6E).
Estrogen upregulates Grx1 and confers protection
against L-BOAA toxicity
Grx1 is constitutively expressed in greater amounts in CNS of
female mice and ovariectomy downregulates Grx1 rendering them
Figure 2. Loss of MMP in Neuro-2a cells correlates with optimum knockdown of Grx1. Cells were transfected with empty vector (control
for 12 and 72 hr; (Fig. 2A)) or shRNA to Grx1 (Fig. 2B) and loss of MMP was monitored after 12, 24, 48 and 72 hr of transfection using JC-1 (2 mg/ml)
dye. Loss of MMP in response to downregulation of Grx1 was found to be maximum after 72 hr of transfection. Green staining represents JC-1
monomer in cells with loss of MMP whereas red staining represents JC-1 aggregates in cells with intact MMP. Bar represents 120 mm.
doi:10.1371/journal.pone.0002459.g002
Figure 1. Localization of Grx1 in cytosol and generation of ROS following its knockdown in Neuro-2a cells. Cells were loaded with
MitoTracker Deep Red 633 (500 nM) for 45 min before fixation and subsequent immunostaining for Grx1 or Grx2. Images were captured using
LSM510 META in confocal microscope. (A) Grx1 (green) does not colocalize with MitoTracker Deep Red 633 (red) in Neuro-2a cells indicating its
cytosolic localization, whereas mitochondrial glutaredoxin 2 (green; Grx2) colocalizes with MitoTracker Deep Red. Bar represents 10 mm. (B)
Quantitation of knockdown of Grx1 as assessed by qRT-PCR, no change observed in Grx2 mRNA levels. Data is represented as mean6SEM from 3
independent experiments. Asterisks indicate values significantly different from controls (p,0.01). (C) Immunoblots depicting Grx1 protein levels in
control (con) and knockdown using shRNA (sh) in Neuro-2a cells and densitometric quantitation of immunoblot after normalization with b-tubulin.
Data is represented as mean6SEM from 3 independent experiments. Asterisks indicate values significantly different from controls (p,0.01). (D)
Immunostaining for Grx1 in Neuro-2a cells transfected with empty vector or shRNA to Grx1. Bar represents 100 mM. (E) Downregulation of Grx1 using
shRNA in Neuro-2a cells enhances ROS production as seen by increased H2DCFDA staining. Bar represents 100 mm.
doi:10.1371/journal.pone.0002459.g001
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and b are expressed in SH-SY5Y cells (Fig. 7A) and treatment with
17-b estradiol upregulated Grx1 as seen by immunostaining
(Fig. 7B) and immunoblot (Fig. 7C). To determine if estrogen
protects against L-BOAA mediated mitochondrial toxicity we
treated the cells with 17-b estradiol (200 nM) 24 hr prior to
Figure 4. Grx1 silencing causes MMP loss which can be prevented by thiol antioxidants and cyclosporine A. SH-SY5Y cells were
transfected with empty vector or shRNA to Grx1 and were used for quantitation of Grx1 at mRNA and protein levels and for the qualitative
observation of MMP loss, 72 hr after the transfection. (A) Immunocytochemistry for Grx1 in cells transfected with shRNA to Grx1 show decreased Grx1
levels as compared to the mock control. Bar represents 100 mm. (B) Quantitation of knockdown of Grx1 mRNA levels as assessed by qRT-PCR in SH-
SY5Y cells transfected with empty vector or shRNA to Grx1. (C) Immunoblots showing optimal knockdown of Grx1 protein levels in cells transfected
with shRNA to Grx1 and densitometric quantitation of immunoblot after normalization with b-tubulin. (D) Loss of MMP was observed in cells
transfected with shRNA to Grx1 but not in the cells transfected with empty vector. Pretreatment of cells with cyclosporine A (10 mM) or a-lipoic acid
(100 mM) prevented the loss of MMP and only the red aggregates of JC-1 representing healthy cells were observed. Bar represents 120 mm.
doi:10.1371/journal.pone.0002459.g004
Figure 3. Quantitative determination of loss of MMP in Neuro-2a cells in response to Grx1 knockdown. Grx1 was downregulated in
Neuro-2a cells using shRNA to Grx1. Cells were treated with vehicle after transfecting them with empty vector, or with vehicle, a-lipoic acid (100 mM)
or cyclosporine A (10 mM), 6 hr after the transfection with shRNA to Grx1. MMP was measured using TMRM as the indicator dye 72 hr after the
transfection. Cells were loaded with TMRM and imaged to measure change in TMRM intensity for 300 sec prior to the addition of CCCP. Loss of TMRM
intensity was further measured for 300 sec after the addition of CCCP. Cells transfected with empty vector show abrupt decrease in TMRM intensity
after CCCP treatment representing sudden loss of MMP (A). Gradual decrease in TMRM intensity in cells transfected with shRNA to Grx1 represents
steady loss of MMP even before CCCP treatment which further decays gradually on its addition (B). MMP was maintained in shRNA transfected cells
pretreated with a-lipoic acid (C) or cyclosporine A (D). The difference in TMRM fluorescence 2 sec prior and 300 sec after CCCP addition was
considered as relative measure of MMP in different groups (E). The data shown are mean6SEM for 25 to 30 cells from 3 independent experiments in
each group. Asterisk indicates values significantly different from controls (p,0.05). Loss of MMP due to the Grx1 knockdown is maintained by
pretreating the cells with a-lipoic acid and cyclosporine A (E). Arrow represents time point of addition of CCCP.
doi:10.1371/journal.pone.0002459.g003
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SY5Y cells using shRNA. Cells were treated with vehicle after transfecting them with empty vector, or with vehicle, a-lipoic acid (100 mM) or
cyclosporine A (10 mM), 6 hr post transfection with shRNA to Grx1 and MMP was measured using TMRM as the indicator dye. Cells were loaded with
TMRM and imaged to measure change in TMRM intensity for 300 sec prior to the addition of CCCP. Loss of TMRM intensity was further measured for
300 sec after the addition of CCCP. (A) Representative fluorescence images of cells transfected with empty vector or shRNA and treated with either
vehicle, a-lipoic acid or cyclosporine A, 100 sec before and 300 sec after addition of CCCP. Bar represents 120 mm. The fluorescence profile in the cell
is represented in the pseudocolor bar. (B) Quantification of change in MMP (Dym). Cells transfected with empty vector show abrupt decrease in
TMRM intensity after CCCP treatment representing sudden loss of MMP (a). Gradual decrease in TMRM intensity in cells transfected with shRNA to
Grx1 represents steady loss of MMP before CCCP treatment, which further decays on adding CCCP (b). MMP was maintained in shRNA transfected
cells pretreated with a-lipoic acid (c) and with cyclosporine A (d). The difference in TMRM fluorescence 2 sec prior and 300 sec after CCCP addition
was considered as relative measure of MMP in different groups (e). The data shown are mean6SEM for 25 to 30 cells from 3 independent
experiments in each group. Asterisks indicate values significantly different from controls (p,0.05). Loss of MMP caused by Grx1 knockdown is
maintained by pretreating the cells with a-lipoic acid (c,e) and cyclosporine A (d,e). Arrow represents time point of addition of CCCP.
doi:10.1371/journal.pone.0002459.g005
Grx1-Mitochondrial Dysfunction
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tively using JC-1 dye. Loss of MMP caused by L-BOAA was
prevented in the cells pretreated with 17-b estradiol, while cells
treated with vehicle were not protected (Fig. 7D). To further
confirm the neuroprotection mediated by estrogen we examined
the cell viability. Cells were treated with vehicle or 17-b estradiol
(200 nM) for 24 hr prior to the treatment with L-BOAA (500 mM)
for further period of 24 hr and cell viability assessed. As compared
to the vehicle treated cells, those exposed to 17-b estradiol had
greater viability indicating that estrogen pretreatment provided
protection against L-BOAA mediated toxicity (Fig. 7E).
Quantitation of loss of MMP using TMRM revealed that cells
pretreated with 17-b estradiol maintained MMP (Fig. 8C) like
controls (Fig. 8A), as compared to the vehicle treated cells
following exposure to L-BOAA (Fig. 8B). The neuroprotection
offered by 17-b estradiol was similar to that seen in cells
overexpressing Grx1 (Fig. 8D). Therefore, both overexpression
of Grx1 or pretreatment of cells with estrogen, which in turn
upregulates Grx1, provide protection against L-BOAA mediated
toxicity in SH-SY5Y cells (Fig. 8E).
Oxidation of thiol groups of voltage dependent anion
channel (VDAC) by Grx1 knockdown
Grx1, a cytosolic enzyme appears critical for maintenance of
mitochondrial integrity; however the underlying mechanism is
unclear. Grx1 is an oxido-reductase and is involved in maintaining
the redox status of several redox sensitive proteins. We therefore
hypothesized that Grx1 may participate in a crosstalk across the
mitochondrial membrane through the modification of mitochon-
drial membrane proteins. VDAC and ANT are components of
mPTP that are present in the outer and inner mitochondrial
membranes, respectively. They are redox sensitive proteins and
can be potentially modulated by Grx1 by altering the redox status
of their thiol groups. Neuro-2a cells were transfected with empty
vector or shRNA to Grx1 and cells were collected after 72 hr and
incubated (derivatized) with AIS, an alkylating agent that binds to
free thiol groups in proteins. AIS derivatized samples were
separated by electrophoresis under non-reducing conditions and
subjected to immunoblotting using antibody to VDAC and ANT.
We observed significantly lower amounts of AIS derivatized
(reduced) VDAC in cells wherein Grx1 was knocked down as
Figure 6. Overexpression of Grx1 prevents loss of MMP and L-BOAA mediated cell toxicity. Grx1 overexpressing SH-SY5Y clonal cell line
and control cell lines electroporated with mock empty vector were characterized for the expression of Grx1 by immunostaining (A), quantitation of
mRNA by qRT-PCR (B) and immunoblot (C). SH-SY5Y cells stably overexpressing Grx1 and those electroporated with empty vector (control) were
exposed to L-BOAA (1 mM) for 24 hr before determining the cell viability. Cells overexpressing Grx1 show more viability after L-BOAA exposure as
compared to the control cells (D). Data is represented as mean6SD from 3 independent experiments. Asterisks indicate values significantly different
from controls (p,0.05). SH-SY5Y clonal lines overexpressing Grx1 and mock control cells were subjected to L-BOAA (1 mM) treatment for 24 hr
before qualitative determination of their MMP status using JC-1 (2 mg/ml). The former (Grx1 overexpressing cell line) maintained MMP following
exposure to L-BOAA while control cells showed loss of MMP detected as green JC-1 monomers (E). Bar represents 120 mm.
doi:10.1371/journal.pone.0002459.g006
Grx1-Mitochondrial Dysfunction
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total VDAC levels (reduced plus oxidized) were unchanged
indicating that VDAC protein was oxidatively modified by Grx1
knockdown. Moreover, ANT, an inner membrane mitochondrial
protein did not show oxidative modification upon downregulation
of Grx1 and the reduced state of ANT was increased significantly
(Fig. 9B), indicating that Grx1 downregulation oxidatively
modifies the redox state of outer membrane but not inner
membrane proteins in the mitochondria.
Discussion
During oxidative stress GSH is oxidized to GSSG (eqn. 1),
which is often effluxed out of the cell thereby preventing the
oxidative modification of protein thiols (PrSH) to protein
glutathione mixed disulfide (PrSSG; eqn. 2). Protein thiols can
also be directly oxidized by ROS to thiyl radicals or in a sequential
manner to sulfenic, sulfinic and sulfonic acid (eqn. 3). Sulfenic
acids can react with GSH to form PrSSG thus preventing their
Figure 7. Estrogen upregulates Grx1 and confers protection against L-BOAA toxicity by maintaining MMP. (A) Immunocytochemical
staining of estrogen receptors a and b in SH-SY5Y cells. Bar represents 100 mm. (B) SH-SY5Y cells were treated with 17-b estradiol (200 nM) for 24 and
48 hr. One set of cells was pretreated with estrogen receptor antagonist ICI 182780 (1 nM), 1 hr prior to the treatment with 17-b estradiol.
Immunostaining for Grx1 shows its upregulation on exposure to 17-b estradiol, which is prevented by ICI 182,780. Bar represents 100 mm. (C)
Immunoblot showing upregulation of Grx1 in response to 17-b estradiol (+Est) as compared with control (Con). Densitometric quantitation of
immunoblot after normalization with b-tubulin. Data is represented as mean6SD from 3 independent experiments. Asterisks indicate values
significantly different from controls (p,0.05). (D) SH-SY5Y cells were exposed to estrogen (200 nM) for 24 hr before treating them with L-BOAA
(1 mM; 24 hr) and loaded with JC-1 for monitoring MMP. L-BOAA mediated loss of MMP was abolished in cells pretreated with estrogen as compared
to vehicle treated controls. Bar represents 120 mm. (E) Cells were pretreated with 17-b estradiol (200 nM) or vehicle for 24 hrs before exposure to L-
BOAA (500 mM; 24 hr). 17-b estradiol protects against L-BOAA mediated cytotoxicity. Data is represented as mean6SD from 3 independent
experiments. Asterisks indicate values significantly different from controls (p,0.05).
doi:10.1371/journal.pone.0002459.g007
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17-b estradiol (200 nM) and cells stably overexpressing Grx1 were treated with L-BOAA (1 mM; 24 hr). Vehicle treated cells show abrupt decrease in
TMRM intensity after CCCP treatment representing sudden loss of MMP (A). Gradual decrease in TMRM intensity in cells treated with L-BOAA
represents steady loss of MMP before CCCP treatment, which further decays on adding CCCP (B). MMP is maintained in SH-SY5Y pretreated with 17-b
estradiol (C) and in cell lines overexpressing Grx1 (D). L-BOAA mediated loss of MMP is prevented by either pretreating the cells with 17-b estradiol or
overexpression of Grx1 (E). Data is represented as mean6SEM from 3 independent experiments. Asterisks indicate values significantly different from
controls (p,0.05). Arrow represents time point of addition of CCCP.
doi:10.1371/journal.pone.0002459.g008
Grx1-Mitochondrial Dysfunction
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further modified to generate intramolecular and intermolecular
protein mixed disulfides (PrSSPr; eqn. 5). PrSSGs are reduced
back to protein thiols very effectively by Grx1 (in the cytosol) and
Grx2 (in the mitochondria) utilizing GSH and reducing equiva-
lents of NADPH (eqn. 6). The GSSG generated by this reaction is
reduced back to GSH by glutathione reductase using reducing
equivalents from NADPH (eqn. 7). Downregulation of Grx1
would therefore potentially lead to increased levels of protein
glutathione mixed disulfides as also mixed disulfides of proteins
(PrSSPr). In addition, generalized increase in ROS in the cell
caused by Grx1 knockdown (Fig. 1) could lead to other non-
specific oxidative events.
2 GSH DCA
ROS
GSSG ð1Þ
PrSHzGSSG?PrSSGzGSH ð2Þ
PrSH DCA
ROS
PrSOH DCA
ROS
PrSO2 H DCA
ROS
PrSO3 H ð3Þ
PrSOHzGSH?PrSSG ð4Þ
PrSSG DCCCCCA
Grx1=GSH=NADPH
PrSHzGSSG ð6Þ
GSSG DCCCCCA
Glutations Reductass
NADPH
GSH ð7Þ
In the present study we demonstrate that the cytosolic protein
disulfide oxido-reductase Grx1, plays an important role in the
maintenance of mitochondrial function and downregulation using
shRNA to Grx1 dramatically alters the mitochondrial membrane
potential which can be restored by a-lipoic acid and cyclosporine
A. a-Lipoic acid, an endogenous thiol antioxidant was very
effective in preventing MMP loss mediated by Grx1 downregu-
lation. The ability of a-lipoic acid to afford protection against the
MMP loss could be due to the fact that the oxidative modification
of protein thiols is restricted to the formation of sulfenic acid and
mixed disulfides which can be reversed enzymatically by
sulfiredoxins and glutaredoxin, respectively [31–34]. If oxidative
modification of protein thiols proceeded from the formation of
Figure 9. Downregulation of Grx1 causes oxidative modifica-
tion of thiol groups of voltage dependent anion channel
(VDAC). Neuro-2a cells were transfected with shRNA to Grx1 or empty
vector and the cell lysates were incubated with AIS which alkylates the
free thiol groups thus causing a shift in the migration on non-reducing
SDS-PAGE. (A) Immunoblot depicting reduced and AIS derivatized
VDAC. Total cell lysate of Neuro-2a cells transfected with empty vector
(shRNA ‘2’) or shRNA to Grx1 (shRNA ‘+’) were subjected to non-
reducing SDS-PAGE. Reduced VDAC measured as such (AIS ‘2’ ) and as
AIS derivatized VDAC (AIS ‘+’), is shown. Total VDAC from control
(shRNA ‘2’) or shRNA to Grx1 (shRNA ‘+’) transfected cells was
measured using reducing SDS-PAGE followed by immunoblotting. (B)
Densitometric measurements of the immunoblots depicted in (A).
Reduced and AIS derivatized VDAC were normalized with total VDAC.
Values are mean6SD (n=6) individual experiments. Asterisks indicate
values significantly different from controls (p,0.01). (C) Immunoblot
depicting reduced and AIS derivatized ANT. Total cell lysate of Neuro-2a
cells transfected with empty vector (shRNA ‘2’) or shRNA to Grx1
(shRNA ‘+’) were subjected to non-reducing SDS-PAGE. Reduced ANT
measured as such (AIS ‘2’) and as AIS derivatized ANT (AIS ‘+’), are
depicted. Total ANT from control (shRNA ‘2’) or shRNA to Grx1 (shRNA
‘+’) transfected cells was measured using reducing SDS-PAGE followed
by immunoblotting. (D) Densitometric measurements of the immuno-
blots shown in (C). Reduced and AIS derivatized ANT were normalized
with total ANT. Values are mean6SD (n=6) individual experiments.
Asterisks indicate values significantly different from controls (p,0.01).
doi:10.1371/journal.pone.0002459.g009
ð5Þ
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irreversible. (Fig. 10). This effect of downregulation of Grx1 was
noted in two neuronal cell lines, SH-SY5Y and Neuro-2a of
human and mouse origin respectively.
MMP is regulated by critical proteins in the mitochondria, such
as VDAC, ANT and cyclophilin. The redox status of these
proteins are known to affect the MMP, for example, the oxidative
state of the vicinal thiol groups in VDAC are known to critically
affect MMP and the opening of mitochondrial permeability
transition pore (mPTP) [36]. Similarly the redox status of ANT is
also known to be crucial for the maintenance of MMP [37–39].
We, therefore examined the redox status of both VDAC and ANT
following downregulation of Grx1 and found that while there was
a dramatic loss of reduced VDAC, ANT did not show a similar
loss. Interestingly there was an increase in the amount of reduced
ANT measured both as the derivatized and the reduced protein.
This could be due to the fact that ANT is unaffected by
downregulation of Grx1 or the mitochondrial glutaredoxin Grx2,
efficiently reduces oxidized ANT. Although the expression of
Grx2, the mitochondrial form of glutaredoxin located predomi-
nantly in the matrix was unchanged when Grx1 was downregu-
lated (Fig. 1B), its potential role in maintaining the reduced state of
key mitochondrial proteins cannot be ruled out.
A recent report has demonstrated the presence of Grx1 in the
intermembrane space in the mitochondria [40]. The knockdown
of Grx1 should potentially downregulate the expression of Grx1
both in the cytosol and the intermembrane space of the
mitochondria, although it is presumable that the turnover rate of
Grx1 could be different in the cytosol and the intermembrane
space of the mitochondria and therefore knockdown of Grx1 may
not be similar in the two subcellular compartments. This may
partly explain the lack of oxidative modification of the cysteine
residue(s) in ANT. The role of Grx1 in redox regulation in the
intermembrane space is yet to be clearly understood and
additional studies are needed in this direction.
Our results point to the fact that the oxidative modification of
VDAC by downregulation of Grx1 could be a major player in
mediating the loss of MMP. Several forms of VDAC are known to
exist, some of which may not have any effect on MMP [41].
However, others have provided evidence for the importance of
VDAC in maintenance of MMP [42–45]. We demonstrate for the
first time that perturbation of the redox milieu in the cytosol
Figure 10. Oxidative modification of thiol groups in proteins: Protein thiols may be oxidized sequentially to sulfenic, sulfinic and sulfonic
acid. Sulfenic acids can react with GSH to form PrSSG thus preventing their irreversible oxidation to sulfonic acids. PrSSG may be further modified to
protein mixed disulfides. PrSSG are reduced back to protein thiols very effectively by Grx1 utilizing GSH and reducing equivalents of NADPH. The thiol
antioxidant, a-lipoic acid, can potentially prevent the oxidative modification of protein thiols.
doi:10.1371/journal.pone.0002459.g010
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potentially result in the observed loss of MMP. Our results also
point that even when the reduced form of ANT is not decreased,
perturbation in VDAC could lead to MMP loss. Since the reduced
form of the inner membrane protein ANT did not decrease by
knockdown of Grx1, we did not monitor the redox status of
cyclophilin D, which resides in the mitochondrial matrix.
L-BOAA is an excitatory amino acid that causes mitochondrial
dysfunction [12,21]. Exposure of SH-SY5Y cells to L-BOAA
resulted in loss of MMP. However, in cells overexpressing Grx1, L-
BOAA was unable to adversely affect MMP or cell viability. Grx1
expression is regulated by estrogen in the central nervous system
(CNS) and overiectomy downregulates Grx1 levels in brain regions
[46]. We were able to detect this phenomenon in SH-SY5Y cells
which express both a and b estrogen receptors. Exposure of cells to
estrogen upregulated Grx1 and prevented L-BOAA mediated loss
of MMP clearly delineating the important role of Grx1 in
maintaining mitochondrial function and thereby the cell viability.
In conclusion, we demonstrate that the downregulation of the
cytosolic Grx1 can lead to mitochondrial dysfunction detected as
loss of MMP which occurs through redox modification of VDAC
but not ANT in the cell lines examined (Fig. 11). Maintenance of
protein thiol homeostasis through Grx1 may play an important
role in disease pathogenesis such as Parkinson’s disease and motor
neuron disease, wherein mitochondrial dysfunction is a key player.
Materials and Methods
L-BOAA was obtained from Research Biochemicals (Natick,
MA). ICI 182,780 and JC-1 were obtained from Tocris Cookson
(Avonmouth, UK) and Molecular Probes respectively (Eugene,
Oregon). Tetramethyl rhodamine methyl ester (TMRM) and
MitoTracker were purchased from Molecular Probes (Eugene,
OR, USA); carbonyl cyanide m-chlorophenylhydrazone (CCCP)
from Aldrich (Milwaukee, WI, USA). Antibody to Grx1 and Grx2
were obtained from Lab Frontiers Life Science Institute (Seoul,
Korea). Antibody to estrogen receptors a and b were obtained
from Santa Cruz Biotechnology Inc., CA. Cell culture products
and Lipofectamine
TM were obtained from Gibco BRL (Invitrogen,
Carlsbad, CA). All other chemicals and reagents were of analytical
grade and were obtained from Sigma Chemical Company (St.
Louis, MO) or Merck (Darmstadt, Germany).
Cells
SH-SY5Y and Neuro-2a cells (American Type Culture Collec-
tion, Manassas, VA, USA) were cultured in MEM and DMEM
medium, respectively, supplemented with 10% (v/v) fetal bovine
serum, 100 units/ml penicillin G and 100 mg/ml streptomycin.
Stable cell lines overexpressing Grx1 and control cell lines
transfected with empty vector, were developed by electroporating
SH-SY5Y cells with 20 mg of pcDNA-pCMV-Grx1 and pcDNA-
3.1 each respectively with a single pulse of 1 ms at 200 V, followed
by clonal selection and expansion. Stable cell lines were maintained
with complete MEM supplemented with 500 mM Geneticin.
Treatment of cells
Regulation of Grx1 by estrogen was studied in SH-SY5Y cells
following differentiation with dibutyryl cyclic AMP (DBA; 1 mM)
for 24 hr. Cells were treated with 17-b-Estradiol (200 nM) for
24 hr further. In some experiments cells were exposed to ICI
182,780 (1 nM), 30 min prior to exposure to estrogen. Differen-
tiated cells pretreated with estradiol or vehicle were treated with L-
BOAA (1 mM) for a further period of 24 hr and used for different
experiments. In some experiments involving the measurement of
MMP, a-lipoic acid (100 mM) or cyclosporine A (10 mM) were
added 6 hr after transfection or along with L-BOAA.
Cell viability assay
MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium
bromide; 5 mg/ml in PBS) was added at a final concentration of
125 mg/ml after treatment or transfection. Cells were incubated
with MTT for 3 hr at 37uC, solubilized in dimethyl formamide
(50%; v/v) and SDS (20%; w/v), prior to measurement of
absorbance at 570 nm.
Downregulation of Grx1
The following oligonucleotide sequences were annealed and
cloned into mU6pro vector kindly provided by Prof. D. Turner,
(Univ. of Michigan, Ann Arbor): 59-TTTGCGGATGCAGT-
GATCTAATAAGTTCTCTATTAGATCACTGCA-TCCGC-
TTTT–39,3 9GCCTACGTCACTAGATTATTCAAGAGATA-
ATCTAGTCACGTAGGCGAAAAAGATC - 59. The construct
was then transfected using Lipofectamine
TM2000 (Invitrogen) into
Neuro-2a or SH-SY5Y as required according to the instructions
provided by the manufacturer. Since there is 87% homology
between mouse and human Grx1, the same shRNA sequence
could be used to downregulate Grx1 expression in cells of both
murine and human origin (Fig. S1).
Immunocytochemistry
SH-SY5Y and Neuro-2a cells were seeded in chamber slides
and fixed with 4% paraformaldehyde (w/v) for each experiment.
Localization of Grx1 was done by loading Neuro-2a cells with
Mito Tracker Deep Red 633 (500 nM) as per manufacturer’s
instruction and then fixed with 3.7% formaldehyde (v/v). Cells
were then immunostained using antiserum to Grx1 (1:500) and
Grx2 (1:500) overnight at 4uC and incubated with secondary
antibody conjugated to Alexa Flour 488 for 1 hr and visualized
under fluorescence microscope. Cells were also immunolabeled for
a and b estrogen receptors.
Intracellular ROS measurement
The oxidant sensitive dye H2DCFDA (29,79-dichlorodihydro-
fluorescein diacetate) was used to measure intracellular ROS. Cells
were seeded at 60% confluency 24 hr prior to transfection with
shRNA to Grx1 or empty vector. After 72 hr of transfection,
Neuro-2a cells were loaded with 10 mMH 2DCFDA dissolved in
dimethyl sulfoxide and incubated for 15 min at 37uC. Cells were
then washed with PBS and imaged using appropriate filter in an
inverted fluorescence microscope.
Quantitative real-time PCR for assessing Grx1 expression
Total RNA was isolated from cells transfected with shRNA to
Grx1, empty vector and stable cell lines overexpressing Grx1 and
used for cDNA synthesis using random hexamers. Quantitative
real time PCR was done for mouse (Mm) and human (Hs) Grx1
using specific primers stated as - Mm-Grx1-forward 59-TCC-
TCAGTCAACTGCCTTTCA-39, Mm-Grx1-reverse 59-CTCC-
GGTGAGCTGTTGTAAA-39 and Hs-Grx1-forward 59-TCGA-
TATCACAGCCACCAAAC-39, Hs-Grx1-reverse 59-CACTG-
CATCCGCCTATACAA-39 respectively. 18S rRNA was used
as internal control for normalization.
Qualitative assessment of MMP using JC-1
JC-1 (5,59,6,69-tetrachloro-1,19,3,39-tetraethylbenzimidazolcar-
bocyanine iodide) is sensitive to mitochondrial membrane
potential and the shift in membrane potential is observed as a
Grx1-Mitochondrial Dysfunction
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mitochondrial membrane potential. After the desired treatment,
cells were loaded with JC-1 (2 mg/ml) for 30 min at 37uC in the
culture medium. The fluorescence intensity of both monomer
(green) and aggregated (J-aggregates, red) molecules were observed
immediately using appropriate filters.
Quantitation of mitochondrial membrane potential by
live cell imaging
Mitochondrial membrane potential was assessed using lipophilic
cationic fluorescent probe, tetramethyl rhodamine methyl ester
(TMRM) that localizes into the mitochondria as a function of
membrane potential. Cells grown on coverslips were loaded with
500 nM TMRM for 30 min at 37uC in Hank’s balanced salt
solution. Real time imaging was performed with a fluorescence
imaging system with a monochromatic light source (TILL
Photonics, Germany) as described earlier [47]. Dye loaded cells
were maintained in a perfusion chamber (bath volume=0.5 ml)
mounted on the microscope stage. Fluorescence images were
recorded every 5 sec using 520 nm excitation and 262 on-chip
binning. Quantification of mitochondrial membrane potential was
performed as described earlier [47]. Regions of interest (ROI)
Figure 11. Cytosolic Grx1 downregulation results in loss of mitochondrial membrane potential: Downregulation of cytosolic Grx1 leads
to modification of critical thiol groups of the outer mitochondrial membrane protein VDAC, resulting in loss of membrane potential which could
eventually lead to cell death. Grx1 expression is regulated by estrogen and its upregulation by estrogen prevents MMP loss by maintaining redox
status of critical thiol groups in the mitochondria.
doi:10.1371/journal.pone.0002459.g011
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change in mitochondrial membrane potential (MMP). To quantify
the MMP, protonophore CCCP was added to depolarize the
mitochondrial membrane and the difference in fluorescence
intensity 10 sec before and 300 sec after CCCP addition was
considered as the relative measure of MMP. Data is represented as
percent relative change in TMRM fluorescence (F/F0)X100,
where F0 and F are the fluorescence intensities at the beginning of
recording and at given time points, respectively.
Redox state of voltage dependent anion channel (VDAC)
and adenine nucleotide translocase (ANT) in Grx1
knocked down cells
Cells were washed with ice cold PBS, harvested and treated with
lysis buffer (16 PBS, 0.5% Igepal v/v). The lysates from control
cells and those transfected with shRNA-Grx1 were incubated
(derivatized) with 4-acetamido-49-((iodoacetyl)amino)stilbene-2,29-
disulfonic acid disodium salt (AIS; 30 mM; Invitrogen, CA) in Tris
buffer (20 mM, pH 7.5), at 25uC for 12 hr and subjected to non-
reducing SDS-PAGE, such that the free thiols in the reduced
proteins were alkylated with AIS and thus could be visualized as a
shift in the blot. The samples that were not derivatized with AIS
were subjected to both non-reducing and reducing SDS-PAGE,
followed by immunoblotting using antibody to VDAC or ANT.
Immunoblot analysis
Cells were washed with PBS and treated with lysis buffer
[50 mM Tris, (pH 7.4), containing NaCl (150 mM), Triton X-100
(1%; v/v), deoxycholic acid sodium salt (1%; w/v), SDS (0.1%)
and EDTA (1 mM)]. Protein concentration was estimated and
lysates were subjected to SDS-PAGE, transferred to PVDF
membrane, and incubated with the antibody to Grx1, followed
by incubation with anti-rabbit IgG labeled with alkaline
phosphatase or horse-radish-peroxidase. Immunostained bands
were detected using nitroblue tetrazolium and 5-bromo-4-chloro-
3-indolyl phosphate as chromogens or using chemiluminescence
kit (ECL, Amersham Pharmacia Biotech, France). All blots were
normalized with b-tubulin.
Statistical analysis was performed using student ‘t’ test, or
ANOVA followed by Student-Newman Keul’s or Dunnett’s test as
appropriate.
Supporting Information
Figure S1 Sequence alignment of mouse (Mus musculus) and
human, (Homo sapiens) cDNA to Grx1 using ClustalW: Sequence
alignment shows 87% homology. The highlighted sequence was
used for generating shRNA, which shows 95% similarity between
mouse and human Grx1.
Found at: doi:10.1371/journal.pone.0002459.s001 (7.06 MB
DOC)
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